-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Written | Edited by Wang Cong | Nagashi Typesetting | Water Written In recent years, stem cell therapy is in the ascendant, and medical research centered on stem cells has also attracted public attention, from anti-aging, hair regeneration, to bone regeneration, immunity enhancement, and more recently New coronary pneumonia treatment and so on, stem cells have brought unlimited possibilities for human medical treatment with their powerful function of promoting tissue regeneration or self-repair.
Stem cell therapy has also brought new light to patients with heart disease.
However, in 2018, as many as 31 research papers on cardiac stem cells by Professor Piero Anversa of Harvard Medical School were withdrawn due to alleged falsification and falsification of experimental data.
Heart stem cells were falsified again.
As a result, the field of stem cell therapy fell into a cold winter.
Fortunately, although cardiac stem cells do not exist, artificially induced pluripotent stem cells (iPSC) can fill this gap.
On April 21, 2021, a research team from the University of California, Los Angeles and the University of Chicago published a titled Patient-derived glial enriched progenitors repair functional deficits due to white matter stroke and vascular dementia in rodents in the Science Translational Medicine journal.
Research papers.
The research team used artificially induced pluripotent stem cells (iPSC) to induce differentiation of glial cells and injected them into the brains of mouse models with symptoms of human stroke and dementia, successfully repairing their brain damage and improving memory function.
This study shows that this iPS-based stem cell therapy can activate the brain's self-repair, prevent the progressive development of brain white matter stroke, and prevent the appearance of dementia.
Dementia can be caused by a variety of conditions, and is characterized by a series of problems including memory, attention, communication, and physical coordination.
The two most common causes of dementia are Alzheimer's disease and brain white matter stroke.
This is a vicious circle.
These two main causes of dementia almost always occur together and promote each other.
There are currently tens of millions of people suffering from dementia in the world, and this number will increase sharply as the population ages.
Currently, there is no therapy that can prevent the development of brain white matter stroke or enhance the brain's ability to repair itself after white matter stroke.
The team used a method invented by Professor Bill Lowry of the University of California, Los Angeles, which quickly generates a large number of nerves by treating artificially induced pluripotent stem cells (iPSC) with a drug called Deferoxamine.
Glial cells.
These glial cells are the cells that surround and support neurons in the central nervous system.
These artificially induced pluripotent stem cells (iPSC) are derived from skin or blood cells that have been reprogrammed into embryonic stem cell-like states, from which scientists can create a theoretically unlimited number of any cell types.
The research team used mouse models with early or mid-stage brain damage similar to human dementia, and injected glial cells into the brains of these mouse models.
After injection, these cells will spread to the damaged area of the brain and secrete growth factors to stimulate brain stem cells to initiate a repair response.
Activating this repair process not only inhibits the process of brain damage, but also enhances the formation of new neural connections and increases the production of myelin, a lipid that covers and protects neuronal connections.
A stroke on the white matter of the brain damaged brain tissue (left) and was repaired by glial cell therapy (right).
Myelin (red) is a lipid that protects the connections between neurons and is lost due to a stroke in the white matter of the brain.
As shown in the picture on the right, glial cell (green) therapy can restore lost myelin and improve connections between brain neurons.
The research team also found that even if these glial cells are eliminated a few months after transplantation, the recovery of the mouse brain will not be affected.
This is because the therapy mainly activates the brain's self-repair by waking up the brain.
Therefore, these transplanted cells do not need to exist for a long time.
This treatment method is different from the therapy using the patient’s own cells.
Although autologous stem cell therapy is also very attractive because patients do not need to take medicine to avoid rejection by the autoimmune system, the disadvantage of autologous stem cell therapy is also obvious, that is, the price is too high.
Expensive, and the cycle is too long, often need to wait for several months.
In the future, if the therapy is proved to be safe and effective through human clinical trials, then researchers can make it into a spot product, mass-produce it and transport it to the hospital for freezing.
For those who have a stroke in the white matter of the brain, they do not have to wait for months, but can receive treatment at the best time.
The research team said that the brain is a particularly good target for cell therapy, because the brain has the so-called "immune privilege".
Foreign worker cells can survive in the brain for a longer period of time without being easily eliminated by the immune system.
Understanding the role of glial cells in repairing brain white matter damage is crucial.
These preliminary results indicate that stem cell therapy based on glial cells may help repair brain white matter strokes and prevent them from further developing into dementia.
It is reported that the research team is currently conducting follow-up experiments to apply for the US Food and Drug Administration (FDA) to approve the therapy for human clinical trials.
Link to the paper: https://stm.
sciencemag.
org/content/13/590/eaaz6747 is open to reprint this article is open to reprint: just leave a message in this article to inform
Stem cell therapy has also brought new light to patients with heart disease.
However, in 2018, as many as 31 research papers on cardiac stem cells by Professor Piero Anversa of Harvard Medical School were withdrawn due to alleged falsification and falsification of experimental data.
Heart stem cells were falsified again.
As a result, the field of stem cell therapy fell into a cold winter.
Fortunately, although cardiac stem cells do not exist, artificially induced pluripotent stem cells (iPSC) can fill this gap.
On April 21, 2021, a research team from the University of California, Los Angeles and the University of Chicago published a titled Patient-derived glial enriched progenitors repair functional deficits due to white matter stroke and vascular dementia in rodents in the Science Translational Medicine journal.
Research papers.
The research team used artificially induced pluripotent stem cells (iPSC) to induce differentiation of glial cells and injected them into the brains of mouse models with symptoms of human stroke and dementia, successfully repairing their brain damage and improving memory function.
This study shows that this iPS-based stem cell therapy can activate the brain's self-repair, prevent the progressive development of brain white matter stroke, and prevent the appearance of dementia.
Dementia can be caused by a variety of conditions, and is characterized by a series of problems including memory, attention, communication, and physical coordination.
The two most common causes of dementia are Alzheimer's disease and brain white matter stroke.
This is a vicious circle.
These two main causes of dementia almost always occur together and promote each other.
There are currently tens of millions of people suffering from dementia in the world, and this number will increase sharply as the population ages.
Currently, there is no therapy that can prevent the development of brain white matter stroke or enhance the brain's ability to repair itself after white matter stroke.
The team used a method invented by Professor Bill Lowry of the University of California, Los Angeles, which quickly generates a large number of nerves by treating artificially induced pluripotent stem cells (iPSC) with a drug called Deferoxamine.
Glial cells.
These glial cells are the cells that surround and support neurons in the central nervous system.
These artificially induced pluripotent stem cells (iPSC) are derived from skin or blood cells that have been reprogrammed into embryonic stem cell-like states, from which scientists can create a theoretically unlimited number of any cell types.
The research team used mouse models with early or mid-stage brain damage similar to human dementia, and injected glial cells into the brains of these mouse models.
After injection, these cells will spread to the damaged area of the brain and secrete growth factors to stimulate brain stem cells to initiate a repair response.
Activating this repair process not only inhibits the process of brain damage, but also enhances the formation of new neural connections and increases the production of myelin, a lipid that covers and protects neuronal connections.
A stroke on the white matter of the brain damaged brain tissue (left) and was repaired by glial cell therapy (right).
Myelin (red) is a lipid that protects the connections between neurons and is lost due to a stroke in the white matter of the brain.
As shown in the picture on the right, glial cell (green) therapy can restore lost myelin and improve connections between brain neurons.
The research team also found that even if these glial cells are eliminated a few months after transplantation, the recovery of the mouse brain will not be affected.
This is because the therapy mainly activates the brain's self-repair by waking up the brain.
Therefore, these transplanted cells do not need to exist for a long time.
This treatment method is different from the therapy using the patient’s own cells.
Although autologous stem cell therapy is also very attractive because patients do not need to take medicine to avoid rejection by the autoimmune system, the disadvantage of autologous stem cell therapy is also obvious, that is, the price is too high.
Expensive, and the cycle is too long, often need to wait for several months.
In the future, if the therapy is proved to be safe and effective through human clinical trials, then researchers can make it into a spot product, mass-produce it and transport it to the hospital for freezing.
For those who have a stroke in the white matter of the brain, they do not have to wait for months, but can receive treatment at the best time.
The research team said that the brain is a particularly good target for cell therapy, because the brain has the so-called "immune privilege".
Foreign worker cells can survive in the brain for a longer period of time without being easily eliminated by the immune system.
Understanding the role of glial cells in repairing brain white matter damage is crucial.
These preliminary results indicate that stem cell therapy based on glial cells may help repair brain white matter strokes and prevent them from further developing into dementia.
It is reported that the research team is currently conducting follow-up experiments to apply for the US Food and Drug Administration (FDA) to approve the therapy for human clinical trials.
Link to the paper: https://stm.
sciencemag.
org/content/13/590/eaaz6747 is open to reprint this article is open to reprint: just leave a message in this article to inform
